Literature DB >> 25816893

Treatment of venous leg ulcers with ultrasound-guided foam sclerotherapy: Healing, long-term recurrence and quality of life evaluation.

Pedro Lloret1, Pedro Redondo1, Juan Cabrera2, Alejandro Sierra2.   

Abstract

Venous leg ulcers (VLU) generally have slow healing rates (HR) and frequent recurrence rates (RR). The underlying etiology is venous hypertension. The present observational cohort study was to determine healing and RR in VLU treated with ultrasound-guided foam sclerotherapy (UGFS). One hundred and eighty VLU were treated with polidocanol microfoam monthly under ultrasound control. Median follow-up was 30 months (range: 17-40). One hundred seventy-two (95.6%) ulcers healed during the study. The overall twenty-four week HR was 79.4% and was significantly higher (95.1%) in patients with isolated great saphenous vein incompetence than in those with great saphenous vein plus perforator (91.7%) or exclusive perforator incompetence (78.9%) (p < 0.01). Patients without deep vein incompetence had a significantly higher 6-month HR (89.8%) than those with (67.4%) (p < 0.01). Multivariate analysis identified the following independent risk factors: chronicity > 12 months (OR 7.69), area > 6 cm(2) (OR 4.24), lipodermatoesclerosis (OR 12.22), history of > 3 previous ulcers (OR 5.57) and history of deep vein thrombosis (OR 6.18). One, two and three year ulcer RR were 8.1%, 14.9%, and 20.8%, respectively. Isolated perforator incompetence and previous history of venous surgery were significantly (p = 0.03) associated with a higher RR. VLU treated with microfoam sclerotherapy are associated with high HR and low mid-term RR.
© 2015 by the Wound Healing Society.

Entities:  

Mesh:

Year:  2015        PMID: 25816893     DOI: 10.1111/wrr.12288

Source DB:  PubMed          Journal:  Wound Repair Regen        ISSN: 1067-1927            Impact factor:   3.617


  7 in total

Review 1.  [Guidelines for sclerotherapy of varicose veins : S2k guideline of the German Society of Phlebology (DGP) in cooperation with the following professional associations: DDG, DGA, DDG, BVP. German Version].

Authors:  E Rabe; F X Breu; I Flessenkämper; H Gerlach; S Guggenbichler; B Kahle; R Murena; S Reich-Schupke; T Schwarz; M Stücker; E Valesky; S Werth; F Pannier
Journal:  Hautarzt       Date:  2021-01       Impact factor: 0.751

Review 2.  Emerging High-Frequency Ultrasound Imaging in Medical Cosmetology.

Authors:  YaPing Tao; Cong Wei; YiMin Su; Bing Hu; Di Sun
Journal:  Front Physiol       Date:  2022-07-04       Impact factor: 4.755

3.  Ultrasound-guided foam sclerotherapy for chronic venous disease with ulcer. A prospective multiple outcome cohort study.

Authors:  Guilherme Camargo Gonçalves de Abreu; Otacílio de Camargo; Márcia Fayad Marcondes de Abreu; José Luis Braga de Aquino
Journal:  J Vasc Bras       Date:  2020-03-10

Review 4.  High-frequency ultrasound in clinical dermatology: a review.

Authors:  Jack Levy; Devon L Barrett; Nile Harris; Jiwoong Jason Jeong; Xiaofeng Yang; Suephy C Chen
Journal:  Ultrasound J       Date:  2021-04-20

Review 5.  Sclerotherapy in the treatment of varicose veins : S2k guideline of the Deutsche Gesellschaft für Phlebologie (DGP) in cooperation with the following societies: DDG, DGA, DGG, BVP.

Authors:  E Rabe; F X Breu; I Flessenkämper; H Gerlach; S Guggenbichler; B Kahle; R Murena; S Reich-Schupke; T Schwarz; M Stücker; E Valesky; S Werth; F Pannier
Journal:  Hautarzt       Date:  2021-12       Impact factor: 0.751

6.  Comparative analysis of endovenous laser ablation versus ultrasound-guided foam sclerotherapy for the treatment of venous leg ulcers.

Authors:  Benedikt Weber; Elias Marquart; Julia Deinsberger; Stanislava Tzaneva; Kornelia Böhler
Journal:  Dermatol Ther       Date:  2022-01-27       Impact factor: 3.858

7.  A retrospective cohort study comparing two treatments for active venous leg ulcers.

Authors:  Xiaochun Liu; Guofu Zheng; Bo Ye; Weiqing Chen; Hailiang Xie; Teng Zhang; Jing Lin
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.